Company intelligence / Profile preview

Sentonix Pharma

Perth, Western Australia, Australiathekids.org.au ↗

Ownership: Private
Development stage: Preclinical

Overview

Setonix Pharmaceuticals is developing orally available immunotherapy drugs aimed at boosting the immune response against cancer. Their approach seeks to improve efficacy and reduce side effects compared to current infusion-based immunotherapies. The company is leveraging research breakthroughs from leading Australian institutions and has received a CUREator grant for its work. No clinical results have been published yet as programs appear pre-clinical or in early development.

Therapeutic areas: Oncology
Modalities: Small molecules (orally available immunotherapy drugs)
Industry: Biotech

Drug pipeline

2 assets

LB1410

Phase 1

Indications: PD-1 resistant tumors

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sentonix Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sentonix Pharma.

Explore the full profile